Loading clinical trials...
Loading clinical trials...
Phase I, Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of a Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation (EP) in Adult Females Previously Immunized With VGX-3100
Conditions
Interventions
VGX-3100
Locations
3
United States
Lyndhurst Gynecologic Associates
Winston-Salem, North Carolina, United States
Laurel Highlands, OB/GYN, P.C.
Hopwood, Pennsylvania, United States
Clinical Research Puerto Rico
San Juan, Puerto Rico
Start Date
July 1, 2010
Primary Completion Date
October 1, 2011
Completion Date
October 20, 2011
Last Updated
August 10, 2018
NCT07209917
NCT04541355
NCT03912831
NCT02308241
Lead Sponsor
Inovio Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions